那格列奈治疗2型糖尿病安全性和有效性的临床观察  

Clinical Evaluation of Efficacy and Safety of Nateglinide in the Treatment of Type 2 Diabetes

作　　者：李玉秀[1] 丁国宪[2] 李启富[3] 陈丽[4] 胡国亮[5] 姬秋和[6] 王守俊[1] 郭妍[2] 罗蓉[3] 候为开[4] 王甫能[5] 张南雁[6] 张雅萍[6] 王姮[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院内分泌科,北京100730 [2]南京医科大学第一附属医院内分泌科,南京210029 [3]重庆医科大学附属第一医院内分泌科,重庆400016 [4]山东大学齐鲁医院内分泌科,济南250012 [5]中山大学附属第一医院内分泌科,广州510080 [6]第四军医大学西京医院内分泌科,西安710032

出　　处：《中国医学科学院学报》2008年第2期211-213,共3页Acta Academiae Medicinae Sinicae

摘　　要：目的评价那格列奈治疗2型糖尿病的有效性和安全性。方法6个中心219例未使用药物、诊断时间>3个月的2型糖尿病患者,共计完成那格列奈组105例、瑞格列奈组114例;观察时间12周,有效性指标为空腹和标准餐后2h血糖、糖化血红蛋白(HbA1c);安全性指标包括肝肾功能、血脂、血尿常规。结果那格列奈和瑞格列奈治疗后HbA1c较治疗前显著降低(P<0·05),但两组间比较差异无显著性。那格列奈和瑞格列奈治疗后空腹和餐后2h血糖较治疗前显著降低(P<0·001),但两组间比较差异无显著性。两组均未见严重不良事件。低血糖事件两组比较差异无显著性。结论那格列奈是安全有效的降血糖药物。Objective To evaluate the efficacy and safety of nateglinide, a new antidiabetic agent, in the treatment of type 2 diabetes. Methods A total of 219 treatment-naive patients with type 2 diabetes from 6 centers were enrolled in this study and blindly divided into nateglinide group （ n = 105 ） and repaglinide group （n = 114）. In all patients, the disease was confirmed for at least three months. The whole observation lasted for 12 weeks. The efficacy indicators measured include glycohemoglobin A1 c （HbA1 c）, fasting blood glucose, and 2 hours postprandial blood glucose, and the safety parameters measured included renal and hepatic function, serum lipids, and blood and urea profiles. Results Similar decreases in fasting blood glucose, 2 hours postprandial blood glucose, and HbAlc were found in both nateglinide group and repaglinide group without significant differences. No severe adverse events were noted. The hypoglycemia event reports were not significantly different between these two groups. Conclusion Nateglinide is an effective and safe drug in treating type 2 diabetes.

关 键 词：那格列奈 瑞格列奈 2型糖尿病 血糖 

分 类 号：R977.15[医药卫生—药品]